Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017

Purpose: Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this conference was to develop an expert consensus-dri

Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia:a Multinational Point Prevalence Study of Hospitalised Patients

Pseudornonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP. The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases. The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients

Delta Scuti Network observations of XX Pyx : detection of 22 pulsation modes and of short-term amplitude and frequency variations

We report multisite observations devoted to the main-sequence δ Scuti star XX Pyx, conducted as the 17th run of the Delta Scuti Network. Over 125 nights a total of 550 h of usable time-series photometric B- and V-filter data were acquired involving both photoelectric and CCD measurements at eight observatories spread around the world, which represents the most extensive single time-series for any pulsating star other than the Sun obtained so far. We describe our observations and reduction methods, and present the frequency analysis of our new data. First, we detect six new pulsation and five new combination frequencies in the star's light curves. We also discover evidence for amplitude and/or frequency variations of some of the modes during the observations. These can occur on time-scales as short as 20 d and show quite diverse behaviour. To take them into account in the frequency analysis, a so-called non-linear frequency analysis method was developed, allowing us to quantify the temporal variability of the modes and to compensate for it. Following that we continue the frequency search and we also incorporate published multisite observations. In this way, we reveal three more pulsation and two more combination frequencies. In the end, we report a total of 30 significant frequencies - 22 of which correspond to independent pulsation modes. This is the largest number of independent modes ever detected in the light curves of a δ Scuti star. The frequencies of the modes show preferred separations as already suggested by previous work on this star; they are also arranged in clear patterns. These results lead to a refinement of the stellar mean density (ṗ = 0.241 ± 0:008 ṗ ̛) and to a new constraint on the rotation rate of XX Pyx vrot = 1.1 ± 0.3d-ˡ: However, our attempts to identify the modes by pattern recognition failed. Moreover, mode identification from multicolour photometry failed as well because the high pulsation frequencies make this method unfavourable. The diverse behaviour of the amplitude and frequency variations of some of the modes leaves resonances as the only presently known possibility for their explanation

Cardiovascular events associated with rofecoxib : final analysis of the APPROVe trial

Background: Selective inhibition of cyclo-oxygenase-2 has been associated with an increased risk of cardiovascular events in several clinical trials. The Adenomatous Polyp Prevention on Vioxx (APPROVe) study assessed the effect of 3-year treatment with a cyclo-oxygenase-2 inhibitor, rofecoxib (25 mg), on recurrence of neoplastic polyps of the large bowel. We report the cardiovascular outcomes of a long-term follow-up of participants in the trial. Methods: The APPROVe study is a multicentre, randomised, placebo-controlled, double-blind trial. 2587 patients with a history of colorectal adenomas were recruited at 108 centres worldwide during 2000 and 2001. Participants were followed for adverse events while on treatment and during the following 14 days. However, after early termination of treatment because of cardiovascular toxicity, we attempted to follow up all randomised patients for at least 1 year after stopping study treatment. External committees blindly assessed potential serious cardiovascular events. The focus of the analysis was the combined incidence of non-fatal myocardial infarction, non-fatal stroke, and death from cardiovascular, haemorrhagic, and unknown causes (Antiplatelet Trialists' Collaboration [APTC] combined endpoint). We used Cox proportional hazards regression to calculate endpoint hazard ratios. The study is registered with ClinicalTrials.gov, number NCT0282386. Findings: We obtained extended post-treatment cardiovascular follow-up data from 84% of participants, and extended mortality follow-up from 95%. In total, 59 individuals had an APTC endpoint in the rofecoxib group and 34 in the placebo group (hazard ratio 1.79, 95% CI 1.17-2.73; p=0.006). In the first year after cessation of treatment, there was a non-significant increase in the risks of APTC endpoints. The APTC hazard ratio did not substantially change over time. Interpretation: Use of rofecoxib is associated with increased rates of APTC events. Study data are compatible with an early increase in risk that persists for one year after stopping treatment